Found 13 articles
Lisa Stockman Mauriello was diagnosed with ALS in January and is seeking access to Biogen’s tofersen (BIIB067) through the Right to Try Act. Her case has reinvigorated the ALS community and its fight for expanded access to investigational therapies for this cruel, always fatal disease.
Prilenia Enrolls First Subject in Europe in its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease
The trial is designed to replicate previous findings of pridopidine demonstrating maintenance of functional capacity in early HD patients and could lead to the registration of pridopidine
Pridopidine was chosen in global competition as one of the top drug candidates to participate in the first ever ALS Platform Trial led by the Healey Center at Massachusetts General Hospital This trial is the second late-stage clinical trial in neurodegenerative disorders with pridopidine, in addition to the global Phase 3 trial in Huntington’s disease
Investors in the fund include a variety of existing and new limited partners, both groups made up of specialized institutional and corporate investors.
Follows very successful 2020, with five major exits/listings: Promedior, KaNDy, Inflazome, Enterprise Therapeutics and Dyne Therapeutics
Prilenia Enrolls First Patients Into its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease in the United States
PROOF-HD is designed to replicate previous findings of pridopidine demonstrating maintenance of functional capacity in early Huntington’s Disease patients
9/21/2020It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, announces the appointment of Henk Schuring as Chief Regulatory and Commercialization Officer.
Forbion, a European life sciences venture capital firm, announced today that it had closed its Forbion Growth Opportunities Fund at $208 million.
Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, announces that is has raised $62.5M in a Series A financing round to launch the Company’s planned HD and ALS late-stage clinical trials. The funding round was led by Forbion and included new investors, Morningside Venture Investments
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety.
AbCellera, a leader in therapeutic antibody discovery from natural immune systems, has appointed Dr. Michael Hayden to its Board of Directors.
The Sean M. Healey & AMG Center for ALS at Mass General aims to speed up the search for new approaches to help patients with amyotrophic lateral sclerosis, through this groundbreaking new trial design which allows for rapid testing of multiple drugs through use of a common trial design